行情

REPH

REPH

Recro Pharma
NASDAQ

实时行情|Nasdaq Last Sale

15.84
-0.04
-0.25%
交易中 15:08 01/27 EST
开盘
15.65
昨收
15.88
最高
16.18
最低
15.63
成交量
12.73万
成交额
--
52周最高
19.00
52周最低
4.957
市值
3.60亿
市盈率(TTM)
-6.7974
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

REPH 新闻

  • 利比亚:几天之内石油生产可能接近完全停止
  • 新浪财经.59分钟前
  • 欧洲央行官员警告称宽松政策加大市场下跌风险
  • 新浪财经.1小时前
  • 美国考虑扩大对旅客筛查力度 以遏制疫情蔓延
  • 新浪财经.1小时前
  • 据悉德国政府上调预期 预计今年经济增长1.1%
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
-0.66%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

REPH 简况

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
展开

Webull提供Recro Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。